<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01653561</url>
  </required_header>
  <id_info>
    <org_study_id>Fudan BR2012-08</org_study_id>
    <nct_id>NCT01653561</nct_id>
  </id_info>
  <brief_title>A Study of Apatinib in Non-triple-negative Metastatic Breast Cancer</brief_title>
  <official_title>A Multi-institutional, Open-label, Single Arm Study of Apatinib in Non-triple-negative Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis of this clinical research study is to discover if the study drug apatinib can&#xD;
      shrink or slow the growth of pretreated non-triple-negative metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Apatinib is a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor&#xD;
      (VEGFR), and its anti-angiogenesis effect has been viewed in preclinical tests. The&#xD;
      investigators' phase I study has shown that the drug's toxicity is manageable and the maximum&#xD;
      tolerable daily dose is 850 mg. The hypothesis of this clinical research study is to discover&#xD;
      if the study drug apatinib can shrink or slow the growth of non-triple-negative breast&#xD;
      cancer. The safety of apatinib will also be studied. Patients physical state, symptoms,&#xD;
      changes in the size of the tumor, and laboratory findings obtained while on-study will help&#xD;
      the research team decide if apatinib is safe and effective in pretreated non-triple-negative&#xD;
      metastatic breast cancer patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS(Progression free survival)</measure>
    <time_frame>8 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR (Objective response rate)</measure>
    <time_frame>8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CBR(Clinical benefit rate)</measure>
    <time_frame>8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS (Overall survival)</measure>
    <time_frame>8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL (Quality of life)</measure>
    <time_frame>8 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity (Number of adverse events)</measure>
    <time_frame>8 Weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Apatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apatinib 500mg/d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>The starting dose of apatinib will be 500mg/d. Two dose reductions will be allowed to 375 and then 250 mg/d.</description>
    <arm_group_label>Apatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        ●≥ 18 and ≤ 70 years of age.&#xD;
&#xD;
          -  ECOG performance status of 0-1.&#xD;
&#xD;
          -  Metastatic breast cancer, confirmed by histological analysis.&#xD;
&#xD;
          -  Have experienced at least 1 and at most 4 regimens, and failed from the last&#xD;
             chemotherapy regimen. Pretreated anthracycline, taxanes and capecitabine (any rational&#xD;
             reason for no use of capecitabine is acceptable) are mandatory.&#xD;
&#xD;
          -  Women diagnosed with human epidermal growth factor receptor positive (HER2+) should&#xD;
             have failed for at least 1 anti-HER2 therapy (any rational reason for no use of&#xD;
             anti-HER2 therapy is acceptable). HER2+ is defined as +++ staining on&#xD;
             immunohistochemistry or FISH/CISH positive for gene amplification.&#xD;
&#xD;
          -  Women diagnosed with HR+ should have failed for at least 1 hormonal therapy.&#xD;
&#xD;
          -  Have failed for at least one chemotherapy regimen, but at most three&#xD;
             regimens(including adjuvant and neo-adjuvant setting).&#xD;
&#xD;
          -  Duration from the last therapy (chemotherapy, radiotherapy, target therapy and&#xD;
             operation) is more than 4 weeks (Duration for nitroso or mitomycin is 6 weeks).&#xD;
&#xD;
          -  Have at least one extracranial measurable site of disease according to RECIST 1.0&#xD;
             criteria that has not been previously irradiated.&#xD;
&#xD;
          -  Life expectancy of more than 3 months.&#xD;
&#xD;
          -  Negative serum or urine pregnancy test taken in all women within 7 days before&#xD;
             inclusion. Sexually active women of childbearing potential must use a medically&#xD;
             acceptable form of contraception from the beginning of the study to 8 weeks after the&#xD;
             last dose of the investigated drug.&#xD;
&#xD;
          -  Written informed consent prior to study specific screening procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Triple-negative breast cancer (ER-, PR- and HER2-. HER2- is defined as 0 or 1+&#xD;
             staining on immunohistochemistry or FISH/CISH negative for gene amplification. )&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  Less than 4 weeks from the last clinical trial.&#xD;
&#xD;
          -  Uncontrolled hypertension with mono-drug therapy (&gt;140/90 mm Hg)；ischemia of the&#xD;
             myocardium （≥ grade 2） or myocardial infarction；arrhythmia（≥ grade 2, QTcF &gt; 470ms for&#xD;
             female patients） or New York Heart Association Class III/IV&#xD;
&#xD;
          -  Any factors that influence the usage of oral administration.&#xD;
&#xD;
          -  The cumulative doses of doxorubicin and epirubicin before inclusion have surpassed 300&#xD;
             mg/m2 and 600 mg/m2, respectively.&#xD;
&#xD;
          -  Duration from the last therapy (chemotherapy, radiotherapy, target therapy and&#xD;
             operation) is less than 4 weeks (Duration for nitroso or mitomycin is less than 6&#xD;
             weeks).&#xD;
&#xD;
          -  Confirmed brain metastasis.&#xD;
&#xD;
          -  Inadequate hepatic, renal, heart, and hematologic functions (hemoglobin &lt;90g/L,&#xD;
             neutrophils &lt; 1.5×10^9/L, platelets &lt; 80×10^9/L , ALT &gt; 2.5 x upper limit of normal&#xD;
             (ULN)(5x for liver metastasis), AST &gt; 2.5 x ULN (5x for liver metastasis), serum&#xD;
             bilirubin &gt; 1.5 x ULN, serum creatine &gt; 1.0 x ULN, creatinine clearance rate ≤&#xD;
             50ml/min, LVEF &lt; lower limit of normal (LLN).&#xD;
&#xD;
          -  Abnormal coagulative function, inclined to bleeding or is receiving&#xD;
             thrombolytictherapy or anticoagulation.&#xD;
&#xD;
          -  History of arterial/venous embolic events (such as cerebrovascular accident, TIA, deep&#xD;
             vein thrombus,and pulmonary embolism)&#xD;
&#xD;
          -  Unhealed wound (&gt; 30 days) or bone fracture.&#xD;
&#xD;
          -  Urine protein ≥++ and confirmed &gt;1.0 g by the 24h quantity.&#xD;
&#xD;
          -  Previous or present history of pulmonary fibrosis,interstitial&#xD;
             pneumonia,pneumoconiosis,radiation pneumonitis,drug-related pneumonitis or&#xD;
             greatly-impaired pulmonary function.&#xD;
&#xD;
          -  Disability of serious uncontrolled intercurrence infection.&#xD;
&#xD;
          -  Abuse of alcohol or drugs.&#xD;
&#xD;
          -  Have received prior treatment with a VEGFR, PDGFR or s-SRC TKI (Bevacizumab is&#xD;
             permitted).&#xD;
&#xD;
          -  Acquired or inherent immunodeficiency； HIV infection； organ transplantation history.&#xD;
&#xD;
          -  The active HBV or HCV infection or HBV DNA ≥10^4/ml.&#xD;
&#xD;
          -  History of other malignancies except cured basal cell carcinoma of skin and carcinoma&#xD;
             in-situ of uterine cervix.&#xD;
&#xD;
          -  Presence of serious harm to subjects or complication to hinder the completion of the&#xD;
             study judged by investigators&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xi-Chun Hu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan Univeristy Cancer Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fudan University Cancer Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>July 10, 2012</study_first_submitted>
  <study_first_submitted_qc>July 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2012</study_first_posted>
  <last_update_submitted>December 2, 2013</last_update_submitted>
  <last_update_submitted_qc>December 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xichun Hu</investigator_full_name>
    <investigator_title>Deputy director of department of medical oncology</investigator_title>
  </responsible_party>
  <keyword>Metastatic breast cancer</keyword>
  <keyword>Apatinib</keyword>
  <keyword>non-triple-negative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

